Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar V Parikh

Showing results (121-130 of 189) with videos related to

Pageof 19
Sort By:
BMC Psychiatry|December 29, 2019
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trialBoadie W Dunlop, Sagar V Parikh, Anthony J Rothschild, et al.
The Journal of Clinical Psychiatry|June 20, 2020
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 ReportRudolf Uher, Benicio N Frey, Lena C Quilty, et al.
Molecular Psychiatry|June 27, 2022
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysisGustavo C Medeiros, Todd D Gould, William L Prueitt, et al.
Bipolar Disorders|August 18, 2010
Association analysis of DAOA and DAO in bipolar disorder: results from two independent case-control studiesDarya Gaysina, Sarah Cohen-Woods, Philip C Chow, et al.
Psychiatry Research|December 28, 2020
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depressionAnthony J Rothschild, Sagar V Parikh, Daniel Hain, et al.
Bipolar Disorders|January 24, 2013
The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and futureLakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, et al.
Psychiatry Research|January 5, 2022
Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorderSagar V Parikh, Rebecca A Law, Daniel T Hain, et al.
Translational Psychiatry|August 22, 2021
Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant responseLaura M Fiori, Massimiliano Orri, Zahia Aouabed, et al.
Pharmacopsychiatry|July 6, 2022
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) StudyHelena K Kim, Gwyneth Zai, Daniel J Müller, et al.
Psychiatry Research|March 13, 2024
Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trialBalwinder Singh, Sagar V Parikh, Jennifer L Vande Voort, et al.
Pageof 19

Showing results (121-130 of 189) with videos related to

Sort By:
Pageof 19
BMC Psychiatry|December 29, 2019
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trialBoadie W Dunlop, Sagar V Parikh, Anthony J Rothschild, et al.
The Journal of Clinical Psychiatry|June 20, 2020
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 ReportRudolf Uher, Benicio N Frey, Lena C Quilty, et al.
Molecular Psychiatry|June 27, 2022
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysisGustavo C Medeiros, Todd D Gould, William L Prueitt, et al.
Bipolar Disorders|August 18, 2010
Association analysis of DAOA and DAO in bipolar disorder: results from two independent case-control studiesDarya Gaysina, Sarah Cohen-Woods, Philip C Chow, et al.
Psychiatry Research|December 28, 2020
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depressionAnthony J Rothschild, Sagar V Parikh, Daniel Hain, et al.
Bipolar Disorders|January 24, 2013
The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and futureLakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, et al.
Psychiatry Research|January 5, 2022
Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorderSagar V Parikh, Rebecca A Law, Daniel T Hain, et al.
Translational Psychiatry|August 22, 2021
Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant responseLaura M Fiori, Massimiliano Orri, Zahia Aouabed, et al.
Pharmacopsychiatry|July 6, 2022
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) StudyHelena K Kim, Gwyneth Zai, Daniel J Müller, et al.
Psychiatry Research|March 13, 2024
Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trialBalwinder Singh, Sagar V Parikh, Jennifer L Vande Voort, et al.
Pageof 19